SCHEMBL20135308

SCHEMBL20135308

CCc1cnc(N2CCN(C(=O)c3ccc([C@@]4(C)NC(=O)NC4=O)cc3)CC2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A7 Q99884 1/20 0.41
MEN1 O00255 4/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.38
P2RY12 Q9H244 2/20 0.37
CRBN Q96SW2 2/20 0.37
MAPT P10636 1/20 0.37
ADAM17 P78536 3/20 0.37
ADAMTS5 Q9UNA0 4/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135310 1.00 SLC6A7 (0.41) SLC6A7MEN1KMT2AALDH1A1P2RY12
SCHEMBL29688668 0.91 LMNA (0.36) SLC6A7MEN1KMT2AALDH1A1MAPT
SCHEMBL20135423 0.91 LMNA (0.36) SLC6A7MEN1KMT2AALDH1A1MAPT
SCHEMBL29688841 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL29688511 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL29688661 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL20134981 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL20135153 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL20135205 0.89 ADAM17 (0.42) SLC6A7MEN1KMT2AADAM17ADAMTS5
SCHEMBL20134932 0.89 ALDH1A1 (0.42) SLC6A7MEN1KMT2AALDH1A1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 SLC6A7 3698/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 SLC6A7 3473/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.